Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.250
+0.011 (4.52%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Theriva Biologics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Theriva Biologics stock have an average target of 2.50, with a low estimate of 1.00 and a high estimate of 4.00. The average target predicts an increase of 900.80% from the current stock price of 0.25.
Analyst Consensus: Buy
* Price targets were last updated on May 7, 2026.
Analyst Ratings
The average analyst rating for Theriva Biologics stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Aug '25 | Nov '25 | Feb '26 | Mar '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Reiterates $1 | Buy | Reiterates | $1 | +300.32% | May 7, 2026 |
| Alliance Global Partners | Alliance Global Partners | Buy Reiterates $4 | Buy | Reiterates | $4 | +1,501.28% | May 6, 2026 |
Financial Forecast
Revenue This Year
300.00K
Revenue Next Year
n/a
from 300.00K
Decreased by -100.00%
EPS This Year
-0.20
from -2.08
EPS Next Year
-0.20
from -0.20
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 300,000 | n/a | |
| Avg | 300,000 | n/a | |
| Low | 300,000 | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | -100.0% | - |
| Avg | -100.0% | - |
| Low | -100.0% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -0.20 | -0.20 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.